Drug-induced systemic lupus erythematosus.

Area of Science:

• Rheumatology
• Clinical Pharmacology
• Immunology

Background:

• Systemic lupus erythematosus (SLE) can be triggered by certain medications, with hydralazine and procainamide being primary culprits.
• The exact cause of SLE remains unknown, though genetic factors play a significant role.
• Over 25 drugs have been implicated, but hydralazine and procainamide account for most confirmed drug-induced SLE cases.

Purpose of the Study:

• To review and compare drug-induced SLE with idiopathic SLE.
• To discuss the implications of using hydralazine and procainamide in patients with idiopathic SLE.
• To highlight key differences and similarities in clinical and laboratory manifestations.

Main Methods:

• Literature review and comparative analysis of drug-induced SLE versus idiopathic SLE.
• Examination of etiological factors, focusing on hydralazine and procainamide.
• Analysis of clinical presentations, demographic data, and laboratory findings.

Main Results:

• Drug-induced SLE, particularly from hydralazine and procainamide, often presents with musculoskeletal symptoms like arthritis.
• Patients with drug-induced SLE are generally older and have a higher male-to-female ratio compared to idiopathic SLE.
• While clinical and lab findings overlap, central nervous system and renal involvement are less common in drug-induced SLE.

Conclusions:

• Hydralazine and procainamide can induce SLE by interacting with nucleoproteins and stimulating antinuclear antibody (ANA) production.
• Baseline ANA testing and careful patient monitoring are recommended before and during therapy with these drugs.
• Limited daily doses of hydralazine (≤200 mg) may mitigate risk, and alternative treatments should be considered for patients with idiopathic SLE who may experience exacerbations from certain drugs.